Upcoming Reports [full schedule to be confirmed]
Schedule of Publications 2025
2025
Oct
Neurology Edition
Corporate Reputation of Pharma 2024/25
Multiple Sclerosis
Corporate Reputation of Pharma 2024/25
Neurodegenerative Edition
Corporate Reputation of Pharma 2024/25
Diabetes Edition
Corporate Reputation of Pharma 2024/25
Published
Sep
Bleeding Disorders Edition
Bleeding disorders edition, Corporate Reputation of Pharma 2024/25
Published
Rare Diseases Edition
Corporate Reputation of Pharma 2024/25, Rare Diseases Edition
Published
Aug
China Edition
Asia Edition, Corporate Reputation of Pharma 2024/25
Published
Japan Edition
Asia Edition, Corporate Reputation of Pharma 2024/25
Published
ANZ Edition
Corporate Reputation of Pharma 2024/25
Published
Italy Edition
Corporate Reputation of Pharma 2024/25, Italy Edition
Published
Jul
Spain Edition
Corporate Reputation of Pharma 2024/25, Spain Edition
Published
Germany Edition
Corporate Reputation of Pharma 2024/25, Germany Edition
Published
France Edition
Corporate Reputation of Pharma 2024/25, France Edition
Published
Jun
Cancer: Prostate Cancer Edition
Cancer Edition, Corporate Reputation of Pharma 2024/25
Published
Cancer: Lung Cancer Edition
Cancer Edition, Corporate Reputation of Pharma 2024/25
Published
Cancer: Blood Cancer Edition
Cancer Edition, Corporate Reputation of Pharma 2024/25
Published
Cancer: Breast Cancer Edition
Cancer Edition, Corporate Reputation of Pharma 2024/25
Published
Cancer: All Cancers Edition
Cancer Edition, Corporate Reputation of Pharma 2024/25
Published
May
Canada Edition
Canada Edition, Corporate Reputation of Pharma 2024/25
Published
UK Edition
Corporate Reputation of Pharma 2024/25, UK Edition
Published
USA Edition
Corporate Reputation of Pharma 2024/25, USA Edition
Published
Apr
Global Edition
Corporate Reputation of Pharma 2024/25, Global Edition
Published
Feb
Environmental, Social & Governance Report 2024
Pharma and ESG
Published
2024
Nov
Neurodegenerative Edition
Corporate Reputation of Pharma 2023/24
Published
Multiple Sclerosis Edition
Corporate Reputation of Pharma 2023/24
Published
Neurology Edition
Corporate Reputation of Pharma 2023/24, Neurological Edition
Published
Oct
Cardiovascular Edition
Cardiovascular Edition, Corporate Reputation of Pharma 2023/24
Published
Patients in Action – Tackling the Healthcare Crisis
Patients in Action
Published
Mental Health Edition
Corporate Reputation of Pharma 2023/24, Mental Health Edition
Published
Sep
Asia Edition
Asia Edition, Corporate Reputation of Pharma 2023/24
Published
Aug
Bleeding Disorders Edition
Bleeding disorders edition, Corporate Reputation of Pharma 2023/24
Published
Rare Diseases Edition
Corporate Reputation of Pharma 2023/24, Rare Diseases Edition
Published
Jul
Spain Edition
Corporate Reputation of Pharma 2023/24, Spain Edition
Published
France Edition
Corporate Reputation of Pharma 2023/24, France Edition
Published
Italy Edition
Corporate Reputation of Pharma 2023/24, Italy Edition
Published
Jun
Germany Edition
Corporate Reputation of Pharma 2023/24, Germany Edition
Published
Cancer Edition II
Cancer Edition, Corporate Reputation of Pharma 2022
Published
Cancer Edition I
Cancer Edition, Corporate Reputation of Pharma 2023/24
Published
May
Canada Edition
Canada Edition, Corporate Reputation of Pharma 2023/24
Published
UK Edition
Corporate Reputation of Pharma 2023/24, UK Edition
Published
USA Edition
Corporate Reputation of Pharma 2023/24, USA Edition
Published
Apr
Global Edition
Corporate Reputation of Pharma 2023/24, Global Edition
Published
2023
Dec
Environmental, Social & Governance Report
New Survey 2023
Published
Nov
Launch of 2023-2024 survey
New Survey 2023
Published
Oct
Neurological Edition [with Multiple Sclerosis]
Corporate Reputation of Pharma 2022, Neurological Edition
Published
Sep
Arthritis Edition
Arthritis Edition
Published
Mental Health Edition
Corporate Reputation of Pharma 2022, Mental Health Edition
Published
Spain Edition
Corporate Reputation of Pharma 2022, Spain Edition
Published
Aug
Ukraine Report
New Survey 2023
Published
Rare Diseases Edition [with Bleeding Disorders]
Bleeding disorders edition, Corporate Reputation of Pharma 2022, Rare Diseases Edition
Published
Australia, New Zealand, China and Japan Edition
Asia Edition, Corporate Reputation of Pharma 2022
Published
Jul
Respiratory Edition
Corporate Reputation of Pharma 2022, Respiratory Edition
Published
France Edition
Corporate Reputation of Pharma 2022, France Edition
Published
Jun
Italy Edition
Corporate Reputation of Pharma 2022, Italy Edition
Published
Germany Edition
Corporate Reputation of Pharma 2022, Germany Edition
Published
Cancer Edition
Cancer Edition, Corporate Reputation of Pharma 2022
Published
May
Canada Edition
Corporate Reputation of Pharma 2022
Published
UK Edition
Corporate Reputation of Pharma 2022, UK Edition
Published
USA Edition
Corporate Reputation of Pharma 2022, USA Edition
Published
Apr
Global Edition
Corporate Reputation of Pharma 2022, Global Edition
Published